MIAMI, FL / ACCESSWIRE / December 20, 2023 / BioVet CGT, Inc. a joint venture of TGI Solar Power Group, Inc., (OTC PINK:TSPG) ("TGI") and BioVet Technologies, Inc. ("BioVet"), announced today it has been formed to commercialize cell and gene therapies for the veterinary space as well as other technologies and therapies for the veterinary market.
"We believe the formation of BioVet CGT is the first commercial effort to provide pet parents with access to first-of-its kind autologous cell and gene therapies for their pets. This venture will not only be highly beneficial to pets and pet parents but will also drive significant shareholder value over the long-term," said Henry Val, chief executive officer of TGI "Together, TGI and BioVet will create a platform, through BioVet CGT, that will provide expanded cell and gene therapy product offerings and access to the rapidly growing veterinary medicine field growth (In 2022, $136.8 billion was spent on our pets in the U.S. In 2023, a total of $143.6 billion in sales is projected in the U.S.). Additionally, BioVet CGT will provide pet parents with other products and technologies which will include intelligent remote monitoring of your pet and preventative diagnostics and products."
"The BioVet CGT team is working to build a platform that provides pet parents with AI targeted therapies, services and quality products at great value with uncompromising quality," said Michael Handley, chief executive officer of BioVet Tech. "Joining forces with TGI through the formation of BioVet CGT will enable predictive disease identification, disease treatment and pet wellness and will improve the lives of pets and pet parents across the United States and abroad."
Management of BioiVet CGT anticipates that it will quickly implement available licensed and develop new technologies that will provide an immediate revenue, by offering our licensed products through BIOVET TECH network of veterinarian hospitals, as well as additional products and service to launch commercially in the beginning of next year. Management is looking forward to initiating pilot testing of our first technology acquisitions in the near term. BioVet CGT will initially focus their efforts on implementing, developing and commercializing the following technologies:
- Companion animal cell and gene therapy
- Cyropreservation of cells
- Genetic testing/screening
- AI-driven disease identification
- Remote patient monitoring and data collection
About Biovet CGT ( www.biovetcgt.com ) : www.biovetcgt.com a veterinarian biotechnology company focused on: discovery and development of novel cell and gene therapies for veterinarian clinics, production of on site by state-of-the-art automated systems, ensures the rapid, efficient, and effective supply of its products directly in the clinical setting. The new assets will be operated under the name BIOTECH CGT and will offer cutting-edge automated systems streamline the therapy delivery, ensuring the best possible outcomes for our animal patients.
About BioVet Technologies ( www.biovet.vet ): BioVet is a veterinary healthcare innovation company dedicated to lowering costs and improving pet quality of life. We accomplish this by focusing on personalized pet care that uses data-driven prediction, prevention, treatment & management.
About TGI Solar: TGI SOLAR POWER GROUP INC. is a diversified holding company. TGI's strategy is to acquire innovative and patented technologies, components, processes, designs, and methods with commercial value that will give competitive market advantage and generate shareholder value.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about TGI Solar Power Group Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
Safe Harbor statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market.
For more info:
Henry Val, CEO of TGI
henryv@tgipower.com
Michael Handley, CEO of BioVet Tech
michael@biovet.vet
SOURCE: TGI Solar Power Group, Inc.
View the original press release on accesswire.com
